Constitution of a Biological Cohort Following Bone Marrow Sampling From MDS or AML Patients and Age-matched Healthy Donors

2017-07-31 12:53:33 | BioPortfolio

Published on BioPortfolio: 2017-07-31T12:53:33-0400

Clinical Trials [2663 Associated Clinical Trials listed on BioPortfolio]

Study Investigating the Interactions of Bone and Hematopoiesis in the Elderly

The prospective BoHemE study is designed to evaluate the correlation between bone marrow function and skeletal health in elderly patients (>= 60 years) with or without pre-existing myelody...

A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes

The primary objective of this study is to determine the safety and tolerability of combined abaloparatide and bevacizumab in patients with Myelodysplastic Syndromes (MDS). A secondary obje...

Fludarabine Based RIC for Bone Marrow Failure Syndromes

This is a pilot study to determine whether fludarabine-based reduced intensity conditioning regimens facilitate successful donor engraftment of patients with acquired aplastic anemia (AA) ...

Impact of 2 Transfusion Strategies on Quality of Life of Multitransfused Patients With Low-risk Myelodysplastic Syndrome

Myelodysplastic syndromes (MDS) are heterogeneous malignant bone marrow disorders characterized by ineffective haematopoiesis, peripheral blood cytopenias and variable risk of leukaemia tr...

Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes

RATIONALE: Collecting and storing samples of blood, bone marrow, and DNA from other tissues from patients with cancer to study in the laboratory may help in the study of cancer. PURPOSE: ...

PubMed Articles [9037 Associated PubMed Articles listed on BioPortfolio]

Evaluation of bone marrow microenvironment could change how myelodysplastic syndromes are diagnosed and treated.

Myelodysplastic syndromes are a heterogeneous group of clonal hematopoietic disorders. However, the therapies used against the hematopoietic stem cells clones have limited efficacy; they slow the evol...

Additional prognostic impact of the percentage of erythroid cells in the bone marrow of patients with myelodysplastic syndromes.

In patients with myelodysplastic syndromes (MDS) the impact of the percentage of erythroid precursors in the bone marrow has been the subject of considerable debate, especially with regard to prognosi...

Profile of fibrosis-related gene transcripts and megakaryocytic changes in the bone marrow of myelodysplastic syndromes with fibrosis.

Bone marrow fibrosis (MF) in myelodysplastic syndromes (MDS) is associated with an adverse prognosis. It is likely that molecular changes similar to those in primary myelofibrosis (PMF) lead to MDS-MF...

Increased Health Care Utilization and Costs during Allogeneic Hematopoietic Cell Transplant for Acute Leukemia and Myelodysplastic syndromes in Adolescents and Young Adults Compared to Children: A Multicenter Study.

Allogeneic hematopoietic cell transplant (HCT) is a curative option for patients with acute leukemia and myelodysplastic syndromes (MDS), but is associated with significant cost. When compared to chil...

Comparison of bone turnover markers in peripheral blood and bone marrow aspirate.

Bone remodeling takes place in the bone marrow environment. We investigated if levels of bone turnover markers (BTMs) differ between bone marrow and peripheral blood, if the bone marrow is an independ...

Medical and Biotech [MESH] Definitions

These growth factors comprise a family of hematopoietic regulators with biological specificities defined by their ability to support proliferation and differentiation of blood cells of different lineages. ERYTHROPOIETIN and the COLONY-STIMULATING FACTORS belong to this family. Some of these factors have been studied and used in the treatment of chemotherapy-induced neutropenia, myelodysplastic syndromes, and bone marrow failure syndromes.

Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.

Clonal myeloid disorders that possess both dysplastic and proliferative features but are not properly classified as either MYELODYSPLASTIC SYNDROMES or MYELOPROLIFERATIVE DISORDERS.

Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as MULTIPLE MYELOMA. Most bone marrow neoplasms are metastatic.

A myelodysplastic-myeloproliferative disease characterized by monocytosis, increased monocytes in the bone marrow, variable degrees of dysplasia, but an absence of immature granulocytes in the blood.

More From BioPortfolio on "Constitution of a Biological Cohort Following Bone Marrow Sampling From MDS or AML Patients and Age-matched Healthy Donors"

Quick Search


Searches Linking to this Trial